Using Convergent Mixed Methods To Evaluate Treatment Risks and Benefits In Rare Disease- An Example From A Phase Ii Registration Trial In Metastatic Merkel Cell Carcinoma
Abstract
Authors
M Bharmal I Guillemin A Marrel J Lambert B Arnould F Fatoumata M Hennessy C Dias-Barbosa